NLS Agreement

The company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company. The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against […]

The companies have signed a collaboration and distribution agreement that gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe. “Partnering with Thermo Fisher, the leading innovator in the HLA industry, is a great opportunity for Devyser and a significant milestone for our company. […]

Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody […]

With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the […]

Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s […]

Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have […]